With respect to ongoing clinical trials, the phase II trial NCT05141357 assesses the effectiveness of the benzamide HDACi Tucidinostat (HBI-8000) in conjunction with the PD-1 inhibitor nivolumab for treating advanced or metastatic NSCLC. Here, PDCD1 is linked to non-small cell lung carcinoma.